| Literature DB >> 24157579 |
Weiwei Shao1, Dong Li1, Jin Peng1, Shaorui Chen1, Chun Zhou1, Zhongbin Cheng1, Yang Yu1, Hong Li1, Cuixian Li1, Yan You1, Yunzi Ma1, Peiqing Liu1, Sheng Yin2, Xiaoyan Shen3.
Abstract
Aristolochia yunnanensis, known as Nan Mu Xiang in traditional Chinese medicine, has long been used to treat hypertension and chest pain. In this study, the effect of ethyl acetate extract of Nan Mu Xiang (NMX) on cardiac fibrosis was assessed in vitro by cultured adult rat cardiac fibroblasts with angiotensin II (AngII) stimulation, and in vivo by rats with abdominal aorta constriction (AAC). In cultured adult rat cardiac fibroblasts stimulated by AngII, NMX inhibited cardiac fibroblast proliferation, reduced the expression of fibronectin, α-smooth muscle actin (α-SMA), and transforming growth factor β (TGF-β) in a dose-dependent manner; and suppressed AngII-induced phosphorylation of extracellular signal-regulated kinase (ERK)1/2, C- rapidly accelerated fibrosarcoma (C-Raf), and small mother against decapentaplegic (Smad) 2. Similar results were also observed in AAC rats with intraperitoneal injection of NMX, which not only ameliorated myocardial fibrosis, but also improved cardiac function. The therapeutic effect of NMX on myocardial fibrosis is attributed mainly to the inhibition of ERK and the TGF-β/Smad signaling pathways. NMX may be a promising potential drug candidate for myocardial fibrosis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24157579 DOI: 10.1016/j.trsl.2013.09.013
Source DB: PubMed Journal: Transl Res ISSN: 1878-1810 Impact factor: 7.012